跳至主要内容
临床试验/NCT01843296
NCT01843296已完成4 期

Comparison of the Effects of Three Methods of Intrathecal Bupivacaine; Bupivacaine-Fentanyl and Bupivacaine-Fentanyl-Magnesium Sulfate on Sensory-Motor Blocks and Postoperative Pain in Patients Undergoing Lumbar Disk Herniation Surgery

Isfahan University of Medical Sciences1 个研究点 分布在 1 个国家目标入组 105 人开始时间: 2012年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
105
试验地点
1
主要终点
The sensory block regression

研究概览

简要总结

The purpose of this study is to Compare three methods of intrathecal bupivacaine; bupivacaine-fentanyl; bupivacaine-fentanyl-magnesium sulfate on sensory-motor blocks and postoperative pain in patients undergoing lumbar disk herniation surgery.

详细描述

  • Comparison three methods of intrathecal bupivacaine;bupivacaine-fentanyl;bupivacaine-fentanyl-magnesium sulfate on sensory-motor blocks in patients undergoing lumbar disk herniation surgery
  • Comparison three methods of intrathecal bupivacaine;bupivacaine-fentanyl;bupivacaine-fentanyl-magnesium sulfate on postoperative pain in patients undergoing lumbar disk herniation surgery
  • Comparison three methods of intrathecal bupivacaine;bupivacaine-fentanyl;bupivacaine-fentanyl-magnesium sulfate on postoperative side effects in patients undergoing lumbar disk herniation surgery

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
20 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Candidate for lumbar disk herniation surgery
  • No contraindication to the spinal anesthesia
  • No history of allergy to opioids and magnesium sulfate
  • No peripheral or central neuropathies
  • No previous history of surgery on same disk level

排除标准

  • Patients with intraoperative tearing of dural suc
  • Occuring of inadvertent intraoperative complications such as bleeding

研究组 & 干预措施

Magnesium

Active Comparator

Patients in group C received a premixed solution of 15 mg hyperbaric bupivacaine 0.5% (3 ml) and 25 µg fentanyl (0.5cc) and 50 mg of magnesium sulfate 50% (0.1 ml) (Pasteur Institute Co, Tehran, Iran) for spinal anesthesia

干预措施: Magnesium Sulfate (Drug)

Magnesium

Active Comparator

Patients in group C received a premixed solution of 15 mg hyperbaric bupivacaine 0.5% (3 ml) and 25 µg fentanyl (0.5cc) and 50 mg of magnesium sulfate 50% (0.1 ml) (Pasteur Institute Co, Tehran, Iran) for spinal anesthesia

干预措施: Spinal Anesthesia (Procedure)

Magnesium

Active Comparator

Patients in group C received a premixed solution of 15 mg hyperbaric bupivacaine 0.5% (3 ml) and 25 µg fentanyl (0.5cc) and 50 mg of magnesium sulfate 50% (0.1 ml) (Pasteur Institute Co, Tehran, Iran) for spinal anesthesia

干预措施: Bupivacaine (Drug)

Magnesium

Active Comparator

Patients in group C received a premixed solution of 15 mg hyperbaric bupivacaine 0.5% (3 ml) and 25 µg fentanyl (0.5cc) and 50 mg of magnesium sulfate 50% (0.1 ml) (Pasteur Institute Co, Tehran, Iran) for spinal anesthesia

干预措施: Fentanyl (Drug)

Fentanyl

Active Comparator

Patients in Fentanyl group received a premixed solution of of 15 mg hyperbaric bupivacaine 0.5% (3 ml) and 25 µg fentanyl (0.5cc),plus 0.1 cc preservative free 0.9% normal saline for spinal anesthesia

干预措施: Spinal Anesthesia (Procedure)

Fentanyl

Active Comparator

Patients in Fentanyl group received a premixed solution of of 15 mg hyperbaric bupivacaine 0.5% (3 ml) and 25 µg fentanyl (0.5cc),plus 0.1 cc preservative free 0.9% normal saline for spinal anesthesia

干预措施: Bupivacaine (Drug)

Fentanyl

Active Comparator

Patients in Fentanyl group received a premixed solution of of 15 mg hyperbaric bupivacaine 0.5% (3 ml) and 25 µg fentanyl (0.5cc),plus 0.1 cc preservative free 0.9% normal saline for spinal anesthesia

干预措施: Fentanyl (Drug)

Bupivacaine

Active Comparator

Patients in Bupivacaine group(control) received a premixed solution of 15 mg of hyperbaric bupivacaine 0.5% (3 ml), plus 0.6 cc preservative free 0.9% normal saline for spinal anesthesia

干预措施: Spinal Anesthesia (Procedure)

Bupivacaine

Active Comparator

Patients in Bupivacaine group(control) received a premixed solution of 15 mg of hyperbaric bupivacaine 0.5% (3 ml), plus 0.6 cc preservative free 0.9% normal saline for spinal anesthesia

干预措施: Bupivacaine (Drug)

结局指标

主要结局

The sensory block regression

时间窗: From intrathecal injection until the sensory block reression to (T10) assessed up to 6 hours

The sensory block regression to (T10) dermatome

The onset of sensory block

时间窗: From intrathecal injection until the onset of sensory block assessed up to 15 minutes

Comparing the onset of sensory blocks to T10 (10th thoracic dermatome) assessed by pinprick test.

The complete motor block

时间窗: From intrathecal injection until the onset of complete motor block assessed up to 15 minutes

Time to complete motor block after intrathecal injection as assess using a modified Bromage scale

The full motor recovery

时间窗: From intrathecal injection until the full motor recovery assessed up to 6 hours

Full motor recovery was defined as zero on the Bromage scale.

The Pain Score

时间窗: The first 24 hours after spinal anesthesia

Using VAS (Visual Analogue Score) system

Time to first analgesic requirement

时间窗: During first 24 hours after spinal anesthesia

Time to first analgesic requirement was measured from the time of spinal injection to the first time at which the patient complained of pain in the postoperative period

次要结局

  • Mean Arterial Blood Pressure(First hour after spinal anesthesia)
  • Heart Rate(First hour after spinal anesthesia)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Fereidoun Mortazavi Najafabadi, MD

fellowship of neuroanesthesia

Isfahan University of Medical Sciences

研究点 (1)

Loading locations...

相似试验